Last update :
19/11/2024
Anticancer drug   Pertuzumab  
injection
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References pdf

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Perjeta Argentina, Australia, Belgium, Brazil, Canada, Chile, Ecuador, Finland, France, Germany, Great Britain, Hungary, Iceland, Ireland, Italy, Japan, Luxembourg, Mexico, Norway, Peru, Romania, Slovenia, Spain, Sweden, Switzerland, Tunisia, Turkey, United States of America
Stability of mixtures   injection   Stability of mixtures : Pertuzumab     
Container Solvent Concentration Compound Temperature Storage Duration of stability References
Polyvinyl chloride Sodium chloride 0,9% 2.7 mg/ml
injection   Pertuzumab   
injection   Trastuzumab 2.3 mg/ml
30°C
24 Hour
Light 3366
Level of evidence B+
Polyvinyl chloride Sodium chloride 0,9% 2.7 mg/ml
injection   Pertuzumab   
injection   Trastuzumab 2.3 mg/ml
5°C
24 Hour
Not specified 3366
Level of evidence B+
Polyolefine Sodium chloride 0,9% 1.5 mg/ml
injection   Pertuzumab   
injection   Trastuzumab 1.5 mg/ml
30°C
24 Hour
Protect from light 3366
Level of evidence B+
Polyolefine Sodium chloride 0,9% 2.7 mg/ml
injection   Pertuzumab   
injection   Trastuzumab 2.3 mg/ml
30°C
24 Hour
Light 3366
Level of evidence B+
Polyolefine Sodium chloride 0,9% 2.7 mg/ml
injection   Pertuzumab   
injection   Trastuzumab 2.3 mg/ml
5°C
24 Hour
Not specified 3366
Level of evidence B+

  Mentions Légales